Newsroom

Sorted by: Latest

-

Amerit Fleet Solutions Appoints Adam Lev as Vice President of Corporate Development to Accelerate Acquisition Strategy

WALNUT CREEK, Calif. & CHARLOTTE, N.C.--(BUSINESS WIRE)--Amerit Fleet Solutions (“Amerit”), the industry’s leading provider of fleet maintenance and fleet solutions, announced the expansion of its strategic acquisition program and the appointment of Adam Lev as Vice President of Corporate Development. This effort, designed to complement Amerit’s history of strong organic growth, builds on the Company’s market-leading position in the fleet solutions industry nationwide. In his role as Vice Presi...
-

Rising Phoenix Capital Announces Successful Full-Cycle Exits Across Multiple Mineral Funds in 2025

DALLAS--(BUSINESS WIRE)--Rising Phoenix Capital, an alternative investment firm operating under Rising Phoenix Resources, today announced the successful full-cycle exits of multiple oil and gas mineral investment funds during 2025, marking a significant milestone for the firm’s income-focused mineral platform. During the year, Rising Phoenix Capital fully divested three mineral-focused vehicles - Rising Phoenix Opportunity Fund I, LLC; Rising Phoenix Royalty Fund III, LP; and Rising Phoenix Opp...
-

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011...
-

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform (“B-Body platform”), e...
-

Pacific Defense Delivers First CMFF MCI Systems Months After Award, Accelerating U.S. Army CMOSS Adoption

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced successful delivery of the first seven Mounted Common Infrastructure (MCI) systems under the U.S. Army’s CMOSS Mounted Form Factor (CMFF) MCI program. Awarded in September 2025, the contract’s initial tranche of systems was delivered within three months of program start, demonstrating rapid execution in direct support of the Army’s accelerated modernization objectives. The early delivery highlights Pacific Defense’s ability to...
-

Valmont Reports Fourth Quarter GAAP EPS of $9.05 and Adjusted EPS of $4.92; Provides Full-Year 2026 EPS Outlook of $20.50 to $23.50

OMAHA, Neb.--(BUSINESS WIRE)--Valmont® Industries, Inc. (NYSE: VMI), a global leader that provides products and solutions to support vital infrastructure and advance agricultural productivity, today reported financial results for the fourth quarter and fiscal year ended December 27, 2025. President and Chief Executive Officer Avner M. Applbaum commented, “In the fourth quarter we delivered improved earnings per share and grew our backlog year-over-year amid a mixed demand environment. During 20...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 16.02.2026 UNCU.LN IE00BD6GCF16 816,921.00 USD 37,330,193.61 45.696  ...
-

Sunoco LP and SunocoCorp LLC Report Solid Fourth Quarter and Full-Year 2025 Financial and Operating Results

DALLAS--(BUSINESS WIRE)--Sunoco LP (NYSE: SUN) (“SUN” or the “Partnership”) and SunocoCorp LLC (NYSE: SUNC) (“SUNC”) today reported financial and operating results for the quarter and year ended December 31, 2025. Fourth Quarter Financial and Operational Highlights Net income attributable to SUN for the fourth quarter of 2025 was $97 million compared to $141 million in the fourth quarter of 2024. Adjusted EBITDA attributable to SUN for the fourth quarter of 2025 was $646 million compared to $43...
-

Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible, second generation Bruton tyrosine kinase inhibitor, for the treatment of relapsed or refractory primar...
-

908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the fourth quarter and full year 2025 before market open on Tuesday, March 3, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “...